Press release from the Competition Council regarding the economic concentration concerning the creation of the company “Viatris Inc” following the merger of the company “Mylan NV” and the company “Upjohn Inc”

In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the “summary of the operation” below, containing the information provided by the parties.

This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.

The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.

The companies involved:

• The company “Mylan NV”;
• The company “Upjohn Inc”

The created company:

• The company “Viatris Inc”

Nature of the operation

• Merger

Economic sectors concerned

• The pharmaceutical production sector.

Deadline for interested third parties to submit their observations

• 10 days from the date of publication of this press release, i.e. November 21, 2024.

NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES

The Competition Council has received notification of an economic concentration operation concerning the creation of the company “Viatris Inc” through the merger of the company “Mylan NV” and the company “Upjohn Inc” a division of the Pfizer group.

“Mylan NV” is a Dutch public limited company whose main activity is the development, manufacture, marketing, and distribution of pharmaceutical products including generic drugs.

“Upjohn Inc” is an American company, established as a targeted division of the Pfizer group, which operated Pfizer’s activities in the field of branded and generic drugs.

“Viatris Inc” is an American company, whose main activity is the development, manufacture, marketing, and distribution of a variety of drugs and health products for the general public.

 

Done in Rabat on November 07, 2024.